4.385
Schlusskurs vom Vortag:
$4.33
Offen:
$4.34
24-Stunden-Volumen:
1.25M
Relative Volume:
0.61
Marktkapitalisierung:
$474.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-240.91M
KGV:
-1.951
EPS:
-2.2476
Netto-Cashflow:
$-202.83M
1W Leistung:
+17.25%
1M Leistung:
+20.80%
6M Leistung:
+29.35%
1J Leistung:
-53.94%
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Firmenname
Rocket Pharmaceuticals Inc
Sektor
Branche
Telefon
646-440-9100
Adresse
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
RCKT
Rocket Pharmaceuticals Inc
|
4.38 | 468.60M | 0 | -240.91M | -202.83M | -2.2476 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.56 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.85 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
765.93 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.64 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
318.65 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-08-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-30 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-05-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-28 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-28 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | Herabstufung | Needham | Buy → Hold |
| 2025-05-27 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-30 | Eingeleitet | Wedbush | Outperform |
| 2024-12-18 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-11-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-11-01 | Eingeleitet | BTIG Research | Buy |
| 2022-07-08 | Eingeleitet | Raymond James | Outperform |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2021-02-18 | Eingeleitet | Needham | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-07-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2019-11-06 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-04-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-03-15 | Eingeleitet | BofA/Merrill | Buy |
| 2019-02-05 | Eingeleitet | Oppenheimer | Outperform |
| 2018-09-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-07-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - The Joplin Globe
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by Monaco Asset Management SAM - MarketBeat
Aug Shorts: What are analysts price targets for Rocket Pharmaceuticals Inc2025 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Is Rocket Pharmaceuticals Inc. Equity Warrant stock good for income investors2025 Trade Ideas & Safe Capital Growth Stock Tips - mfd.ru
How Rocket Pharmaceuticals Inc. Equity Warrant stock performs in rising dollar environmentTrade Exit Report & Daily Profit Maximizing Trade Tips - mfd.ru
Analysts Recommend Rocket Pharmaceuticals as a Top Buy - Intellectia AI
Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery - Finviz
Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,253 Shares - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Insider John Militello Sells 3,726 Shares - MarketBeat
Why Rocket Pharmaceuticals Inc. stock could rally in 2025Trade Risk Assessment & Daily Risk Controlled Trade Plans - mfd.ru
Is Rocket Pharmaceuticals Inc. stock a good pick for beginnersJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - mfd.ru
Aug Outlook: What are analysts’ price targets for Rocket Pharmaceuticals Inc.July 2025 Fed Impact & High Return Trade Opportunity Guides - mfd.ru
Gains Recap: Is Rocket Pharmaceuticals Inc. Equity Warrant forming a breakout pattern2025 Stock Rankings & Momentum Based Trading Signals - mfd.ru
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Should I average down on Rocket Pharmaceuticals Inc. stockJuly 2025 Sector Moves & Verified Chart Pattern Signals - mfd.ru
Market Overview: Is Rocket Pharmaceuticals Inc forming a bullish divergence2025 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Stock Recap: Should I trade or invest in Rocket Pharmaceuticals Inc Equity WarrantJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
Recap Report: What are analysts price targets for Rocket Pharmaceuticals IncMarket Risk Analysis & Smart Money Movement Tracker - baoquankhu1.vn
Earnings Report: Is Rocket Pharmaceuticals Inc showing insider buyingJuly 2025 Drop Watch & Weekly Momentum Picks - baoquankhu1.vn
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
FOMO Trade: Does LOOP have a sustainable dividendWeekly Trade Summary & Short-Term High Return Strategies - baoquankhu1.vn
Patterns Watch: Is AMWL stock forming a triangle pattern2025 Valuation Update & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Is Rocket Pharmaceuticals Inc. Equity Warrant a stock for growth or value investorsEarnings Performance Report & Free Verified High Yield Trade Plans - mfd.ru
Aug Summary: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stockPortfolio Update Summary & Long-Term Growth Stock Strategies - baoquankhu1.vn
Aug Movers: Is Rocket Pharmaceuticals Inc exposed to political riskPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
Is now the right time to enter Rocket Pharmaceuticals Inc. Equity WarrantQuarterly Trade Report & Technical Confirmation Trade Alerts - mfd.ru
Undervalued Penny Stocks To Consider In January 2026 - Yahoo Finance
Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Fundamentals Check: What are analysts price targets for Rocket Pharmaceuticals IncWeekly Stock Recap & Community Supported Trade Ideas - baoquankhu1.vn
Rocket Pharmaceuticals, Inc. (RCKT) Investor Outlook: Unpacking A Potential 102% Upside - DirectorsTalk Interviews
Breakout Zone: Is Rocket Pharmaceuticals Inc Equity Warrant stock good for income investorsJuly 2025 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Pullback Watch: What is the long term forecast for Rocket Pharmaceuticals Inc stock - baoquankhu1.vn
ETF Watch: Is BIPC stock heavily shortedJuly 2025 Pullbacks & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Price Action: Is FCNCP stock suitable for long term investing2025 Fundamental Recap & Daily Chart Pattern Signals - baoquankhu1.vn
Aug Decliners: What is Rocket Pharmaceuticals Incs 5 year growth outlookWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Will The FDA's Decision On KRESLADI Propel Rocket Pharmaceuticals? - RTTNews
RCKT: 2026 will see key clinical milestones and a potential first commercial launch in gene therapy - TradingView
Will Rocket Pharmaceuticals Inc benefit from sector rotationJuly 2025 Volume & Technical Pattern Alert System - baoquankhu1.vn
Value Recap: What Wall Street predicts for Rocket Pharmaceuticals Inc stock priceMarket Performance Report & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Summary: Why Rocket Pharmaceuticals Inc Equity Warrant stock remains undervaluedM&A Rumor & AI Enhanced Trade Execution Alerts - Bộ Nội Vụ
Fundamentals Check: How buybacks impact Rocket Pharmaceuticals Inc. stock value2025 Pullback Review & Reliable Trade Execution Plans - Bộ Nội Vụ
Rocket Pharmaceuticals Shares Gain on FDA Green Light for Gene Therapy Targeting Heart Failure - MSN
Earnings Beat: Can Rocket Pharmaceuticals Inc expand into new markets2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
How Rocket Pharmaceuticals Inc. Equity Warrant stock performs in weak economyMarket Sentiment Report & AI Powered Buy/Sell Recommendations - ulpravda.ru
Published on: 2026-01-10 12:46:55 - Улправда
Rocket Pharmaceuticals, Inc.Common Stock (NQ: RCKT - FinancialContent
Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a 100% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Will Rocket Pharmaceuticals Inc. Equity Warrant stock rally after Fed decisionsJuly 2025 Movers & Precise Entry and Exit Recommendations - ulpravda.ru
Cash per share of Rocket Pharmaceuticals, Inc. Warrant 2023- on Rocket Pharmctc – NASDAQ:RCKTW - TradingView — Track All Markets
Why Rocket Pharmaceuticals Inc. stock could outperform in 2025Take Profit & Short-Term Swing Trade Alerts - Улправда
Finanzdaten der Rocket Pharmaceuticals Inc-Aktie (RCKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rocket Pharmaceuticals Inc-Aktie (RCKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
Feb 18 '26 |
Sale |
3.34 |
5,990 |
19,995 |
1,046,055 |
| Wilson Martin | General Counsel |
Feb 18 '26 |
Sale |
3.34 |
1,376 |
4,593 |
682,000 |
| Wilson Martin | General Counsel |
Feb 13 '26 |
Sale |
3.31 |
12,253 |
40,582 |
683,376 |
| Militello John | See Remarks |
Feb 13 '26 |
Sale |
3.31 |
3,726 |
12,341 |
92,176 |
| Shah Gaurav | CEO |
Feb 13 '26 |
Sale |
3.31 |
12,279 |
40,668 |
1,052,045 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):